UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Reported): May 29, 2024 (May 22, 2024)
NATIONAL HEALTH INVESTORS INC
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | |
| Maryland | | 001-10822 | | 62-1470956 |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
222 Robert Rose Drive, Murfreesboro, TN 37129
(Address of principal executive offices)
(615) 890-9100
(Registrant's telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Title of each Class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Common Stock, $0.01 par value | | NHI | | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
(1)The Company’s annual meeting of stockholders was held on May 22, 2024 at The View at Fountains, 1500 Medical Center Parkway, Suite 1D, Murfreesboro, Tennessee 37129. As of the record date, there were a total of 43,424,841 shares of Common Stock outstanding and entitled to vote at the annual meeting. At the annual meeting, 37,006,346 shares of Common Stock were represented in person or by proxy; therefore, a quorum was present.
(2)Set forth below are the matters acted upon by the Company’s stockholders at the annual meeting and the final voting results on each such matter.
(1)The nominees named below were elected to serve as members of the Board of Directors of the Company for a three-year term until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified, and the voting results were as follows:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| Nominee | | Votes For | | Votes Against | | Abstentions | | Broker Non-Votes |
| D. Eric Mendelsohn | | 30,820,578 | | 280,067 |
| 946,910 | | 4,958,791 |
| Charlotte A. Swafford | | 20,745,812 | | 10,365,642 | | 936,101 | | 4,958,791 |
| Robert T. Webb | | 19,211,271 | | 11,890,320 | | 945,964 | | 4,958,791 |
(2)The compensation paid to NHI’s named executive officers was approved with the following voting results:
| | | | | | | | | | | | | | | | | | | | |
| Votes For | | Votes Against | | Abstentions | | Broker Non-Votes |
| 29,685,288 | | 1,338,532 | | 1,023,735 | | 4,958,791 |
(3) The selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, and the voting results were as follows:
| | | | | | | | | | | | | | |
| | | | | |
| Votes For | | Votes Against | | Abstentions |
| 36,477,341 | | 480,667 | | 48,338 |
Additionally, Tracy M. J. Colden was appointed as the Chair of the Nominating and Corporate Governance Committee effective May 22, 2024, replacing James R. Jobe, who remains a member of the committee.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
National Health Investors, Inc.
By: /s/ John L. Spaid
Name: John L. Spaid
Title: Chief Financial Officer
Date: May 29, 2024
